Skip to main content
logo
McKesson Corporation (MCK)
NYSE: MCK · Real-Time Price · USD
907.99
-13.39 (-1.45%)
At close: Sep 4, 2026, 4:00 PM EDT
923.64
+15.65 (1.72%)
After-hours: Sep 4, 2026, 7:54 PM EDT

Revenue

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17
North American Pharmaceutical Revenue
340.70B336.65B304.51B
Oncology & Multispecialty Revenue
51.99B48.42B36.86B
Prescription Technology Solutions Revenue
5.94B5.81B5.22B
Medical Surgical Solutions Revenue
11.63B11.51B11.38B
Other Segment Revenue
-1.04B1.09B
Revenue (Other)
738.00M--
Revenue (Total)
410.98B403.43B359.05B

EBIT

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17
North American Pharmaceutical Operating Profit
3.97B3.66B2.95B
Oncology & Multispecialty Operating Profit
1.26B1.15B767.00M
Prescription Technology Solutions Operating Profit
1.02B1.04B875.00M
Medical Surgical Solutions Operating Profit
839.00M938.00M779.00M
Other Segment Operating Profit
-590.00M54.00M
Operating Income (Other)
-590.00M-1.17B-998.00M
Operating Income (Total)
6.50B6.21B4.42B

Capital Expenditures

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17
US Pharmaceutical Capital Expenditures
241.00M
Prescription Technology Solutions Capital Expenditures
11.00M
Medical Surgical Solutions Capital Expenditures
163.00M
International Capital Expenditures
107.00M